FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007679672> ?p ?o ?g. }

• W2007679672 endingPage "1360" @default.
• W2007679672 startingPage "1351" @default.
• W2007679672 abstract "Longer duration of first-line chemotherapy for patients with metastatic breast cancer is associated with prolonged overall survival and improved progression-free survival. We investigated capecitabine added to maintenance bevacizumab after initial treatment with bevacizumab and docetaxel in this setting.We did this open-label randomised phase 3 trial at 54 hospitals in Brazil, China, Egypt, France, Hong Kong, India, Italy, Poland, Spain, and Turkey. We enrolled patients with HER2-negative measurable metastatic breast cancer; each received three to six cycles of first-line bevacizumab (15 mg/kg) and docetaxel (75-100 mg/m(2)) every 3 weeks. Progression-free patients were randomly assigned with an interactive voice-response system by block (size four) randomisation (1:1) to receive either bevacizumab and capecitabine or bevacizumab only (bevacizumab 15 mg/kg on day 1; capecitabine 1000 mg/m(2) twice per day on days 1-14, every 3 weeks) until progression, stratified by oestrogen receptor status (positive vs negative), visceral metastases (present vs absent), response status (stable disease vs response vs non-measurable), and lactate dehydrogenase concentration (≤1·5 vs >1·5 × upper limit of normal). Neither patients nor investigators were masked to allocation. The primary endpoint was progression-free survival (from randomisation) in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT00929240.Between July 16, 2009, and March 7, 2011 (when enrolment was prematurely terminated), 284 patients received initial bevacizumab and docetaxel; 185 (65%) were randomly assigned (91 to bevacizumab and capecitabine versus 94 to bevacizumab only). Progression-free survival was significantly longer in the bevacizumab and capecitabine group than in the bevacizumab only group (median 11·9 months [95% CI 9·8-15·4] vs 4·3 months [3·9-6·8]; stratified hazard ratio 0·38 [95% CI 0·27-0·55]; two-sided log-rank p<0·0001), as was overall survival (median 39·0 months [95% CI 32·3-not reached] vs 23·7 months [18·5-31·7]; stratified HR 0·43 [95% CI 0·26-0·69]; two-sided log-rank p=0·0003). Results for time to progression were consistent with those for progression-free survival. 78 (86%) patients in the bevacizumab and capecitabine group and 72 (77%) in the bevacizumab only group had an objective response. Clinical benefit was recorded in 92 (98%) patients in the bevacizumab alone group and 90 (99%) in the bevacizumab and capecitabine group. Mean change from baseline in global health score did not differ significantly between groups. Grade 3 or worse adverse events during the maintenance phase were more common with bevacizumab and capecitabine than with bevacizumab only (45 [49%] of 91 patients vs 25 [27%] of 92 patients). The most common grade 3 or worse events were hand-foot syndrome (28 [31%] in the bevacizumab and capecitabine group vs none in the bevacizumab alone group), hypertension (eight [9%] vs three [3%]), and proteinuria (three [3%] vs four [4%]). Serious adverse events were reported by ten (11%) patients in the bevacizumab and capecitabine group and seven (8%) patients in the bevacizumab only group.Despite prematurely terminated accrual and the lack of information about post-progression treatment, both progression-free survival and overall survival were significantly improved with bevacizumab and capecitabine compared with bevacizumab alone as maintenance treatment. These results might inform future maintenance trials and current first-line treatment strategies for HER2-negative metastatic breast cancer.F Hoffmann-La Roche." @default.
• W2007679672 created "2016-06-24" @default.
• W2007679672 creator A5005580223 @default.
• W2007679672 creator A5013164903 @default.
• W2007679672 creator A5015202957 @default.
• W2007679672 creator A5018432685 @default.
• W2007679672 creator A5019412832 @default.
• W2007679672 creator A5032431292 @default.
• W2007679672 creator A5033082338 @default.
• W2007679672 creator A5036532311 @default.
• W2007679672 creator A5053893942 @default.
• W2007679672 creator A5064035855 @default.
• W2007679672 creator A5080181504 @default.
• W2007679672 creator A5085322664 @default.
• W2007679672 date "2014-11-01" @default.
• W2007679672 modified "2023-10-01" @default.
• W2007679672 title "Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial" @default.
• W2007679672 cites W1964586143 @default.
• W2007679672 cites W1968260891 @default.
• W2007679672 cites W1971211622 @default.
• W2007679672 cites W1978450356 @default.
• W2007679672 cites W1981065236 @default.
• W2007679672 cites W1985573146 @default.
• W2007679672 cites W1989796113 @default.
• W2007679672 cites W2008778169 @default.
• W2007679672 cites W2075610273 @default.
• W2007679672 cites W2092507930 @default.
• W2007679672 cites W2103563357 @default.
• W2007679672 cites W2126275851 @default.
• W2007679672 cites W2128002599 @default.
• W2007679672 cites W2128967324 @default.
• W2007679672 cites W2138734774 @default.
• W2007679672 cites W2140103603 @default.
• W2007679672 cites W2143481677 @default.
• W2007679672 cites W2148858542 @default.
• W2007679672 cites W2160373161 @default.
• W2007679672 cites W2167224460 @default.
• W2007679672 cites W2169210177 @default.
• W2007679672 cites W2171244965 @default.
• W2007679672 cites W2171611244 @default.
• W2007679672 cites W2999619211 @default.
• W2007679672 cites W2999983310 @default.
• W2007679672 doi "https://doi.org/10.1016/s1470-2045(14)70444-9" @default.
• W2007679672 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25273343" @default.
• W2007679672 hasPublicationYear "2014" @default.
• W2007679672 type Work @default.
• W2007679672 sameAs 2007679672 @default.
• W2007679672 citedByCount "116" @default.
• W2007679672 countsByYear W20076796722014 @default.
• W2007679672 countsByYear W20076796722015 @default.
• W2007679672 countsByYear W20076796722016 @default.
• W2007679672 countsByYear W20076796722017 @default.
• W2007679672 countsByYear W20076796722018 @default.
• W2007679672 countsByYear W20076796722019 @default.
• W2007679672 countsByYear W20076796722020 @default.
• W2007679672 countsByYear W20076796722021 @default.
• W2007679672 countsByYear W20076796722022 @default.
• W2007679672 countsByYear W20076796722023 @default.
• W2007679672 crossrefType "journal-article" @default.
• W2007679672 hasAuthorship W2007679672A5005580223 @default.
• W2007679672 hasAuthorship W2007679672A5013164903 @default.
• W2007679672 hasAuthorship W2007679672A5015202957 @default.
• W2007679672 hasAuthorship W2007679672A5018432685 @default.
• W2007679672 hasAuthorship W2007679672A5019412832 @default.
• W2007679672 hasAuthorship W2007679672A5032431292 @default.
• W2007679672 hasAuthorship W2007679672A5033082338 @default.
• W2007679672 hasAuthorship W2007679672A5036532311 @default.
• W2007679672 hasAuthorship W2007679672A5053893942 @default.
• W2007679672 hasAuthorship W2007679672A5064035855 @default.
• W2007679672 hasAuthorship W2007679672A5080181504 @default.
• W2007679672 hasAuthorship W2007679672A5085322664 @default.
• W2007679672 hasConcept C121608353 @default.
• W2007679672 hasConcept C126322002 @default.
• W2007679672 hasConcept C141071460 @default.
• W2007679672 hasConcept C143998085 @default.
• W2007679672 hasConcept C168563851 @default.
• W2007679672 hasConcept C203092338 @default.
• W2007679672 hasConcept C2775930923 @default.
• W2007679672 hasConcept C2776694085 @default.
• W2007679672 hasConcept C2777802072 @default.
• W2007679672 hasConcept C2777909004 @default.
• W2007679672 hasConcept C2780739268 @default.
• W2007679672 hasConcept C2781190966 @default.
• W2007679672 hasConcept C2908647359 @default.
• W2007679672 hasConcept C526805850 @default.
• W2007679672 hasConcept C530470458 @default.
• W2007679672 hasConcept C71924100 @default.
• W2007679672 hasConcept C99454951 @default.
• W2007679672 hasConceptScore W2007679672C121608353 @default.
• W2007679672 hasConceptScore W2007679672C126322002 @default.
• W2007679672 hasConceptScore W2007679672C141071460 @default.
• W2007679672 hasConceptScore W2007679672C143998085 @default.
• W2007679672 hasConceptScore W2007679672C168563851 @default.
• W2007679672 hasConceptScore W2007679672C203092338 @default.
• W2007679672 hasConceptScore W2007679672C2775930923 @default.
• W2007679672 hasConceptScore W2007679672C2776694085 @default.
• W2007679672 hasConceptScore W2007679672C2777802072 @default.
• W2007679672 hasConceptScore W2007679672C2777909004 @default.

• next